Latest news with #ElementBiosciences
Business Wire
22-05-2025
- Business
- Business Wire
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. 'This collaboration builds on our existing relationship with Element, which has yielded Twist's on-market Element-native kit and 1-hour fast hybridization Trinity solution. Twist will have exclusive access to develop additional library prep and target enrichment workflows compatible with Element's Trinity sequencing technology, giving Element customers access to the uniformity, consistency and quality provided by our NGS tools,' said Emily M. Leproust, CEO and co-founder of Twist Bioscience. 'This will further advance Twist and Element's shared goal to radically streamline hybrid capture processes both off and on the sequencer. With the expansion of our co-development and commercial efforts, we will be able to further serve critical markets such as agbio, population genomics and clinical research. Adapting our broadly compatible and innovative NGS workflows to work on Element's sequencing platform demonstrates the broad applicability and versatility of our NGS products and enables customers flexibility to choose the system that best meets their needs without sacrificing uniformity or quality delivered through the Twist portfolio.' "By uniting our revolutionary Trinity workflow for targeted sequencing with Twist's superior library preparation capabilities, we're creating an integrated solution that further catalyzes access to premium life science tools and accelerates scientific discovery across every field,' said Molly He, CEO and co-founder of Element Biosciences. 'Our partnership with Twist reflects both our companies' drive to remove barriers that have constrained innovation in this space for far too long." The collaboration between Twist and Element will enable researchers to access end-to-end workflows from library prep through sequencing on Element's AVITI platform, which offers high-quality sequencing and flexibility. Under the collaboration, Twist will be the exclusive partner of these new library prep and target enrichment workflows, expanding the existing Trinity offerings beyond exome sequencing and delivering industry-leading performance across key NGS applications. Twist and Element will engage in joint commercial and promotional activities to improve customer access to these innovative solutions. About Element Biosciences, Inc. Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit and follow us on LinkedIn, X (Twitter), and Facebook. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Business Wire
24-04-2025
- Business
- Business Wire
Element Biosciences Accelerates Rollout of Direct in Sample Sequencing for the AVITI24™ Intelligent Multiomics System to Meet Growing Demand
SAN DIEGO--(BUSINESS WIRE)-- Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the accelerated rollout and availability of direct in sample sequencing on AVITI24, the first intelligent multiomics system. Direct in sample sequencing, or DISS, is a high-demand and transformative technology that unlocks unprecedented research possibilities across a variety of new use cases, including lineage tracing and CRISPR screens with simultaneous optical phenotyping, targeted RNA sequencing, custom protein analysis, and more – all completely library-prep free. Direct in sample sequencing technology will be available for preorder May 21, 2025. "Direct in sample sequencing is a leap forward that removes any and all library prep entirely, enabling scientists to profile RNA, proteins, phosphoproteins, and cell morphology from a single sample in one automated run. It opens the door to smart, scalable biology—shifting the field to high-resolution, high-value insights at unprecedented speed," said Michael Previte, Co-founder and Chief Technology Officer of Element Biosciences. New research from the AVITI24 platform, including abstracts and workshop sessions, will be presented at the American Association for Cancer Research (AACR) annual meeting in Chicago from April 25-30. Attendees can meet the Element team at Booth #4035 and Meeting Room MR-119. AACR abstract presentations exploring new upgrades to the AVITI24 platform are listed below and can also be found on our website. An automated workflow for optical pooled screens with massively multiplexed phenotypic readouts on AVITI24 Sunday, April 27, 2:00 PM - 5:00 PM Avtar Singh, PhD, Genentech LB042 | Section 52 A cancer patient survival study facilitated by an integrated enrichment workflow streamlined DNA and RNA sequencing of biopsy samples Sunday, April 27, 2:00 PM - 5:00 PM June Zhao, PhD 1020 /22 - Section 42 Unraveling the mechanism of action for research of cancer therapies using AVITI24 Monday, April 28, 2:00 PM - 5:00 PM Vivian Dien, PhD 3702 /1-Section 47 A novel integrated target capture and rapid sequencing workflow for myeloid malignancy mutation detection within 12 hours Tuesday, April 29, 9:00 AM - 12:00 PM Kyle S. Metcalfe 4080 /17 - Section 10 To learn more about DISS and AVITI24, book a meeting with Element at AACR via Calendly. About Element Biosciences, Inc. Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit and follow us on LinkedIn, X (Twitter), and Facebook.
Associated Press
22-04-2025
- Business
- Associated Press
GENE SOLUTIONS AND ELEMENT BIOSCIENCES ENTER STRATEGIC COLLABORATION TO ADVANCE NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGY GLOBALLY
HO CHI MINH CITY, April 22, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have entered into a strategic collaboration. The collaboration was formalized with the signing of a Memorandum of Understanding (MoU) during Element Biosciences' visit to Gene Solutions' laboratory. This collaboration aims to create significant synergies by combining Element Biosciences' groundbreaking sequencing platforms with Gene Solutions' innovative technologies in genetic solutions. Element Biosciences has rapidly emerged as a leading innovator in the next generation sequencing (NGS) field, delivering novel solutions that provide exceptional performance and flexibility for researchers. Gene Solutions, with its comprehensive portfolio of genetic tests, leveraging NGS and artificial intelligence, has reached over 4,500 hospitals and clinics in eight Asian countries and is actively expanding its global footprint. Equity in Reproductive Health: Accessibility of Non-invasive Prenatal Testing (NIPT) NIPT is one of the most well-known clinical applications of NGS technology worldwide. The test screens for genomic abnormalities in cell-free DNA fragments released from the placenta into the mother's blood[1] and is recommended for all pregnant women from 9-10 weeks of gestation. Over the past eight years, Gene Solutions has developed a strong portfolio of NIPT (trademarked as triSureTM ) and a comprehensive ecosystem for reproductive health from pre-birth to newborn and postnatal diagnosis. The company uniquely integrates recessive diseases and dominant single-gene disorders screening in a single workflow with NIPT, leveraging its AI platform and optimized lab protocols. Currently, Gene Solutions is researching the incorporation of pregnancy complications prediction into the NIPT test. The NIPT market was valued at USD 5.20 billion in 2022 and is projected to grow to USD 19.09 billion by 2030[2]. Gene Solutions seeks to leverage Element's accessible and affordable research solutions to support its aim to bring safe, accurate, and non-invasive screening tools to all pregnant women. Precision Oncology: Advancing Cancer Care with Genomic Insights and Cutting-Edge Technology Early detection is paramount in the fight against cancer. Gene Solutions has commercialized its AI-powered, clinically validated SPOT-MAS test, which has demonstrated strong efficacy in identifying cancers at early stages and those lacking established screening methods[3,4,5]. For cancer patients, the company has developed tailored solutions for selecting targeted therapies and immunotherapies, uniquely combining genomic and transcriptomic tumor profiling with personalized cancer monitoring ( K-TRACK, K-4CARE ) [6]. Research to support these advancements are made possible by the readiness of NGS platforms and AI algorithms. The collaboration between the two companies aims to further accelerate the research supporting integration of Gene Solution's advanced cancer care tools into clinical practice globally. Research into these advancements is made possible through AVITI24™, Element Biosciences' first-of-its-kind multiomics platform. In addition to providing highly accurate NGS readouts, AVITI24 delivers simultaneous in situ transcriptomic, proteomic, and morphological profiling at single-cell resolution through its powerful Teton™ kits and assays. Powered by Element's proprietary avidite base chemistry (ABC) sequencing, AVITI24 with Teton provides a direct window into complex biological mechanisms and pathways — paving the way for breakthrough discoveries. AVITI24 will deliver the scalable, unified multi-dimensional data that has long eluded researchers, and ultimately will accelerate the pace of scientific research. Gene Solutions will leverage this cutting-edge platform in its research pipelines, including the Clinical Multi-omics Project, 3D Patient-derived Organoids, and Neoantigen Cancer Vaccine pipeline. These initiatives represent the company's visionary approach to incorporating Multi-modal AI and Multi-omics insights to unlock next frontiers in therapeutic development. NGS Testing and Precision Medicine Accessibility Dr. Nguyen Huu Nguyen, Deputy CEO of Gene Solutions, expressed: 'Our foundation is in the research and development of genetic solutions. By combining Element Biosciences' powerful platform with Gene Solutions' expertise and market reach, we are confident that we can significantly enhance the accessibility and application of genomic advances.' Edwin Hauw, Senior Vice President of Marketing & Product Management at Element Biosciences, added: 'Our collaboration with Gene Solutions will combine the best of both our worlds: Element's revolutionary AVITI24 multiomics and AVITI sequencing platforms, and Gene Solutions expertise in bringing transformative genetic solutions to the APAC region. Together, we will elevate the research supporting the real-world impact these genetic testing solutions have downstream on patient outcomes.' The MoU sets a framework for discussions on strategic partnerships, marketing efforts, customer-centric and technical support, and research and development opportunities. This collaboration promises to leverage the expertise of both parties to enhance genomics research, clinical research applications, and market accessibility for both companies' global strategies. About Gene Solutions Gene Solutions, a multinational biotech company, offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. The testing services include cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. Established in 2017, Gene Solutions operates a network of seven NGS laboratories, including two central CAP-accredited laboratories in Singapore and Vietnam. With over two million tests provided to patients, we remain committed to delivering accessible genetic testing services to more than 4,500 hospitals and clinics across Singapore, Vietnam, Thailand, Indonesia, Malaysia, the Philippines, Hong Kong, and Taiwan. To learn more about Gene Solutions, please visit Media Contact: [email protected] About Element Biosciences, Inc. Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific research. To learn more about Element, please visit and follow us on LinkedIn, X (Twitter), and Facebook. Media Contact: [email protected] References: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd
Korea Herald
22-04-2025
- Business
- Korea Herald
GENE SOLUTIONS AND ELEMENT BIOSCIENCES ENTER STRATEGIC COLLABORATION TO ADVANCE NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGY GLOBALLY
HO CHI MINH CITY, April 22, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have entered into a strategic collaboration. The collaboration was formalized with the signing of a Memorandum of Understanding (MoU) during Element Biosciences' visit to Gene Solutions' laboratory. This collaboration aims to create significant synergies by combining Element Biosciences' groundbreaking sequencing platforms with Gene Solutions' innovative technologies in genetic solutions. Element Biosciences has rapidly emerged as a leading innovator in the next generation sequencing (NGS) field, delivering novel solutions that provide exceptional performance and flexibility for researchers. Gene Solutions, with its comprehensive portfolio of genetic tests, leveraging NGS and artificial intelligence, has reached over 4,500 hospitals and clinics in eight Asian countries and is actively expanding its global footprint. Equity in Reproductive Health: Accessibility of Non-invasive Prenatal Testing (NIPT) NIPT is one of the most well-known clinical applications of NGS technology worldwide. The test screens for genomic abnormalities in cell-free DNA fragments released from the placenta into the mother's blood [1] and is recommended for all pregnant women from 9-10 weeks of gestation. Over the past eight years, Gene Solutions has developed a strong portfolio of NIPT (trademarked as triSure TM) and a comprehensive ecosystem for reproductive health from pre-birth to newborn and postnatal diagnosis. The company uniquely integrates recessive diseases and dominant single-gene disorders screening in a single workflow with NIPT, leveraging its AI platform and optimized lab protocols. Currently, Gene Solutions is researching the incorporation of pregnancy complications prediction into the NIPT test. The NIPT market was valued at USD 5.20 billion in 2022 and is projected to grow to USD 19.09 billion by 2030 [2]. Gene Solutions seeks to leverage Element's accessible and affordable research solutions to support its aim to bring safe, accurate, and non-invasive screening tools to all pregnant women. Early detection is paramount in the fight against cancer. Gene Solutions has commercialized its AI-powered, clinically validated SPOT-MAS test, which has demonstrated strong efficacy in identifying cancers at early stages and those lacking established screening methods [3,4,5]. For cancer patients, the company has developed tailored solutions for selecting targeted therapies and immunotherapies, uniquely combining genomic and transcriptomic tumor profiling with personalized cancer monitoring (K-TRACK, K-4CARE) [6]. Research to support these advancements are made possible by the readiness of NGS platforms and AI algorithms. The collaboration between the two companies aims to further accelerate the research supporting integration of Gene Solution's advanced cancer care tools into clinical practice globally. Research into these advancements is made possible through AVITI24™, Element Biosciences' first-of-its-kind multiomics platform. In addition to providing highly accurate NGS readouts, AVITI24 delivers simultaneous in situ transcriptomic, proteomic, and morphological profiling at single-cell resolution through its powerful Teton™ kits and assays. Powered by Element's proprietary avidite base chemistry (ABC) sequencing, AVITI24 with Teton provides a direct window into complex biological mechanisms and pathways — paving the way for breakthrough discoveries. AVITI24 will deliver the scalable, unified multi-dimensional data that has long eluded researchers, and ultimately will accelerate the pace of scientific research. Gene Solutions will leverage this cutting-edge platform in its research pipelines, including the Clinical Multi-omics Project, 3D Patient-derived Organoids, and Neoantigen Cancer Vaccine pipeline. These initiatives represent the company's visionary approach to incorporating Multi-modal AI and Multi-omics insights to unlock next frontiers in therapeutic development. NGS Testing and Precision Medicine Accessibility Dr. Nguyen Huu Nguyen, Deputy CEO of Gene Solutions, expressed:"Our foundation is in the research and development of genetic solutions. By combining Element Biosciences' powerful platform with Gene Solutions' expertise and market reach, we are confident that we can significantly enhance the accessibility and application of genomic advances." Edwin Hauw, Senior Vice President of Marketing & Product Management at Element Biosciences, added:"Our collaboration with Gene Solutions will combine the best of both our worlds: Element's revolutionary AVITI24 multiomics and AVITI sequencing platforms, and Gene Solutions expertise in bringing transformative genetic solutions to the APAC region. Together, we will elevate the research supporting the real-world impact these genetic testing solutions have downstream on patient outcomes." The MoU sets a framework for discussions on strategic partnerships, marketing efforts, customer-centric and technical support, and research and development opportunities. This collaboration promises to leverage the expertise of both parties to enhance genomics research, clinical research applications, and market accessibility for both companies' global strategies. About Gene Solutions Gene Solutions, a multinational biotech company, offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. The testing services include cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. Established in 2017, Gene Solutions operates a network of seven NGS laboratories, including two central CAP-accredited laboratories in Singapore and Vietnam. With over two million tests provided to patients, we remain committed to delivering accessible genetic testing services to more than 4,500 hospitals and clinics across Singapore, Vietnam, Thailand, Indonesia, Malaysia, the Philippines, Hong Kong, and Taiwan. To learn more about Gene Solutions, please visit Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific research. To learn more about Element, please visit and follow us on LinkedIn, X (Twitter), and Facebook. Media Contact:
Malaysian Reserve
22-04-2025
- Business
- Malaysian Reserve
GENE SOLUTIONS AND ELEMENT BIOSCIENCES ENTER STRATEGIC COLLABORATION TO ADVANCE NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGY GLOBALLY
HO CHI MINH CITY, April 22, 2025 /PRNewswire/ — Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have entered into a strategic collaboration. The collaboration was formalized with the signing of a Memorandum of Understanding (MoU) during Element Biosciences' visit to Gene Solutions' laboratory. This collaboration aims to create significant synergies by combining Element Biosciences' groundbreaking sequencing platforms with Gene Solutions' innovative technologies in genetic solutions. Element Biosciences has rapidly emerged as a leading innovator in the next generation sequencing (NGS) field, delivering novel solutions that provide exceptional performance and flexibility for researchers. Gene Solutions, with its comprehensive portfolio of genetic tests, leveraging NGS and artificial intelligence, has reached over 4,500 hospitals and clinics in eight Asian countries and is actively expanding its global footprint. Equity in Reproductive Health: Accessibility of Non-invasive Prenatal Testing (NIPT) NIPT is one of the most well-known clinical applications of NGS technology worldwide. The test screens for genomic abnormalities in cell-free DNA fragments released from the placenta into the mother's blood[1] and is recommended for all pregnant women from 9-10 weeks of gestation. Over the past eight years, Gene Solutions has developed a strong portfolio of NIPT (trademarked as triSureTM) and a comprehensive ecosystem for reproductive health from pre-birth to newborn and postnatal diagnosis. The company uniquely integrates recessive diseases and dominant single-gene disorders screening in a single workflow with NIPT, leveraging its AI platform and optimized lab protocols. Currently, Gene Solutions is researching the incorporation of pregnancy complications prediction into the NIPT test. The NIPT market was valued at USD 5.20 billion in 2022 and is projected to grow to USD 19.09 billion by 2030[2]. Gene Solutions seeks to leverage Element's accessible and affordable research solutions to support its aim to bring safe, accurate, and non-invasive screening tools to all pregnant women. Precision Oncology: Advancing Cancer Care with Genomic Insights and Cutting-Edge Technology Early detection is paramount in the fight against cancer. Gene Solutions has commercialized its AI-powered, clinically validated SPOT-MAS test, which has demonstrated strong efficacy in identifying cancers at early stages and those lacking established screening methods[3,4,5]. For cancer patients, the company has developed tailored solutions for selecting targeted therapies and immunotherapies, uniquely combining genomic and transcriptomic tumor profiling with personalized cancer monitoring (K-TRACK, K-4CARE) [6]. Research to support these advancements are made possible by the readiness of NGS platforms and AI algorithms. The collaboration between the two companies aims to further accelerate the research supporting integration of Gene Solution's advanced cancer care tools into clinical practice globally. Research into these advancements is made possible through AVITI24™, Element Biosciences' first-of-its-kind multiomics platform. In addition to providing highly accurate NGS readouts, AVITI24 delivers simultaneous in situ transcriptomic, proteomic, and morphological profiling at single-cell resolution through its powerful Teton™ kits and assays. Powered by Element's proprietary avidite base chemistry (ABC) sequencing, AVITI24 with Teton provides a direct window into complex biological mechanisms and pathways — paving the way for breakthrough discoveries. AVITI24 will deliver the scalable, unified multi-dimensional data that has long eluded researchers, and ultimately will accelerate the pace of scientific research. Gene Solutions will leverage this cutting-edge platform in its research pipelines, including the Clinical Multi-omics Project, 3D Patient-derived Organoids, and Neoantigen Cancer Vaccine pipeline. These initiatives represent the company's visionary approach to incorporating Multi-modal AI and Multi-omics insights to unlock next frontiers in therapeutic development. NGS Testing and Precision Medicine Accessibility Dr. Nguyen Huu Nguyen, Deputy CEO of Gene Solutions, expressed: 'Our foundation is in the research and development of genetic solutions. By combining Element Biosciences' powerful platform with Gene Solutions' expertise and market reach, we are confident that we can significantly enhance the accessibility and application of genomic advances.' Edwin Hauw, Senior Vice President of Marketing & Product Management at Element Biosciences, added: 'Our collaboration with Gene Solutions will combine the best of both our worlds: Element's revolutionary AVITI24 multiomics and AVITI sequencing platforms, and Gene Solutions expertise in bringing transformative genetic solutions to the APAC region. Together, we will elevate the research supporting the real-world impact these genetic testing solutions have downstream on patient outcomes.' The MoU sets a framework for discussions on strategic partnerships, marketing efforts, customer-centric and technical support, and research and development opportunities. This collaboration promises to leverage the expertise of both parties to enhance genomics research, clinical research applications, and market accessibility for both companies' global strategies. About Gene Solutions Gene Solutions, a multinational biotech company, offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. The testing services include cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. Established in 2017, Gene Solutions operates a network of seven NGS laboratories, including two central CAP-accredited laboratories in Singapore and Vietnam. With over two million tests provided to patients, we remain committed to delivering accessible genetic testing services to more than 4,500 hospitals and clinics across Singapore, Vietnam, Thailand, Indonesia, Malaysia, the Philippines, Hong Kong, and Taiwan. To learn more about Gene Solutions, please visit Contact: pr@ About Element Biosciences, Inc. Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific research. To learn more about Element, please visit and follow us on LinkedIn, X (Twitter), and Contact: media@ References: [1] ACOG current guidance, accessed 04 April 2025.[2] Fortune Business Insights.[3] Nguyen, L. H. D., et al. (2025). Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Medicine, 23(1).[4] Carbonell, Chantelle, et al. Cancer Control 31 (2024).[5] Thien Nguyen, Chi Van, et al. 'Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests.' Future Oncology (2024): 1-11.[6] Van-Anh Nguyen Hoang, et al. Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors. JCO Oncology Advances 2, e2400084 (2025).
